Editas Medicine, Inc. (EDIT) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Editas Medicine, Inc.
Address
11 Hurley Street
Cambridge, MA 02141
United States of America (the)
Phone
617 401 9000
Sector
Healthcare
Industry
Biotechnology
Employees
87
First IPO Date
February 03, 2016
Key Executives
| Name | Title | Pay | Year Born |
| Gilmore O'Neill | President, Chief Executive Officer & Director | 1.07M | 1964 |
| Amy Parison | Senior Vice President & Chief Financial Officer | 555,520 | 1986 |
| Linda C. Burkly | Executive Vice President & Chief Scientific Officer | 734,972 | 1957 |
| Feng Zhang | Co-Founder & Scientific Advisory Board Member | 0 | N/A |
| George McDonald Church | Co-Founder & Scientific Advisory Board Member | 0 | 1954 |
| Frank Panaccio | Senior Vice President & Chief Business Officer | 0 | N/A |
| Damien Grierson | Senior Vice President, General Counsel & Corporate Secretary | 0 | N/A |
| Tom Love | Vice President of People | 0 | N/A |
| Brieana Buckley | Senior Vice President of Development and Program Leadership | 0 | N/A |
| Gregory Whitehead | Executive Vice President and Chief Technical & Quality Officer | 0 | N/A |
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
